GSK621 CAS No.:1346607-05-3

GSK621 CAS No.:1346607-05-3 is a highly effective inhibitor of the SGK family of protein kinases, a group of proteins which have become increasingly important in the fields of cancer and cardiovascular research. This compound has been shown to be highly specific, meaning that it targets only the SGK kinase family, which makes it an ideal candidate for use in both research and therapeutic applications.

One of the key benefits of using GSK621 is its ability to inhibit the growth and spread of cancer cells. This is achieved through its ability to suppress the activity of the SGK pathway, which plays a key role in the regulation of a number of cellular processes, including cell growth, proliferation, and survival. By inhibiting this pathway, GSK621 is able to effectively reduce the viability and proliferation of cancer cells, making it a promising candidate for use in the treatment of a range of human cancers.

In addition to its anticancer properties, GSK621 also possesses a range of other therapeutic benefits, including its ability to prevent the development of cardiovascular disease. By inhibiting the activity of the SGK pathway, GSK621 is able to reduce the risk of hypertension, renal dysfunction, and other cardiovascular complications, making it a valuable tool for the management of chronic conditions such as diabetes, metabolic syndrome, and obesity.

One of the key advantages of GSK621 over other inhibitors of the SGK kinase family is its exceptional specificity, which allows it to target only those kinases that are involved in the development and progression of cancer and cardiovascular disease. This means that it is less likely to cause unwanted side effects or toxicity, making it an attractive option for researchers and clinicians looking for a safe, effective, and specific therapy.

Furthermore, GSK621 is highly soluble and bioavailable, which means that it can be easily administered in a range of different forms, including capsules, tablets, and intravenous injections. This makes it a versatile and convenient therapeutic option for a range of different applications, from basic preclinical research to advanced clinical trials and beyond.

In conclusion, GSK621 is a highly promising compound with a range of valuable therapeutic applications in the fields of cancer and cardiovascular research. Its exceptional specificity, low toxicity, and convenient formulation make it an ideal candidate for use in a range of different settings, from basic scientific studies to more advanced clinical applications. So, it is a perfect product for merchants looking for an effective and specific inhibitor of the SGK kinase family with a range of therapeutic benefits.

Chemical Structure : GSK621

CAS No.: 1346607-05-3

 

GSK621(GSK 621;GSK-621)

Catalog No.: URK-V624 Only Used For Lab.

GSK621 (GSK-621) is a potent, specific AMPK agonist (activator), induces cytotoxicity in AML (IC50=13-30 uM) but not in normal hematopoietic cells.

Biological Activity

GSK621 (GSK-621) is a potent, specific AMPK agonist (activator), induces cytotoxicity in AML (IC50=13-30 uM) but not in normal hematopoietic cells.
GSK621 is more potent than A-769662 at inducing AMPK activation, as measured by the level of ACC phosphorylation, markedly increases phosphorylation at AMPKα T172 in AML cell lines (MOLM-14, HL-60, and OCI-AML3) and primary AML samples.
Cytotoxicity in AML cells from GSK621 involves the eIF2α/ATF4 signaling pathway that specifically results from mTORC1 activation.

Physicochemical Properties

References

1. Sujobert P, et al. Cell Rep. 2015 Jun 9;11(9):1446-57.

2. Jiang H, et al. PLoS One. 2016 Aug 17;11(8):e0161017.

3. Chen L, et al. Biochem Biophys Res Commun. 2016 Nov 25;480(4):515-521.

4. Liu W, et al. Oncotarget. 2017 Feb 7;8(6):10543-10552

URK-V624_COA

URK-V624_SDS

URK-V624_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We take pride in our reputation for producing high-quality PI3K/Akt/mTOR Pathway Library products and services.
• Through continuous improvement of technical support and quality control capabilities, we are able to provide customers with a full range of more valuable and competitive GSK621 CAS No.:1346607-05-3.
• Our factory strives to produce PI3K/Akt/mTOR Pathway Library products that meet or exceed customer expectations.
• The company insists on taking integrity as the core, innovation as the goal, and perfect after-sales service as the guarantee. We start with customer requirements, and end with customer satisfaction, all for the benefit of customers!
• We are dedicated to delivering the very best PI3K/Akt/mTOR Pathway Library products and services to our clients.
• The company is committed to providing technical products and professional services to the industry and making greater contributions to the development of the industry.
• We offer superior PI3K/Akt/mTOR Pathway Library products and services with unparalleled customer support.
• We are commitment to offer the competitive price, outstanding products quality, as well as fast delivery for GSK621 CAS No.:1346607-05-3.
• At our factory, we believe in working closely with our customers to provide tailor-made PI3K/Akt/mTOR Pathway Library solutions.
• We insist on technological innovation, continue to satisfy customers, and constantly practice arduous entrepreneurship.

Hot Tags: gsk621 cas no.:1346607-05-3, China gsk621 cas no.:1346607-05-3, inhibitors for enzyme activity, agonists for steroid receptor activation, nf b pathway glycomics, agonists for joint repair, epigenetic library for epigenetic attenuation, epigenetic library for epigenetic analysis of epigenetic genotype